TickerTalks
Browse all tickers →
TickerTalks›$SLBT
SLSLBT

SL Science Holding Ltd

$SLBT·$25M·Biotechnology·Healthcare
$2.65-1.7%1Y-66.1%
Mentions · last 7 days
2026-07-26: 0 posts2026-07-27: 1 posts2026-07-28: 0 posts2026-07-29: 2 posts2026-07-30: 1 posts2026-07-31: 0 posts2026-08-01: 0 posts4+25%
Price updated 3d ago·X counts updated 2d ago
SLSLBT
$SLBTSL Science Holding Ltd
$2.65-1.67%4 posts+25%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $SLBT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellWinding up for a moveAI verdict · as of 2026-08-01

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

SL Science glioblastoma cell-therapy — recent SPAC combination, GDT orphan-drug request submitted, $25M cap.

SL Science Holding is a Taiwan-based clinical-stage biopharmaceutical company developing gamma-delta T-cell (GDT) therapy for glioblastoma multiforme (brain cancer) — recently listed on Nasdaq via a business combination with Horizon Space Acquisition II Corp. Down 66% over 12 months as post-SPAC-listing valuation adjusted — the recent orphan drug designation request to the FDA for GDT cell therapy targeting glioblastoma is the substantive regulatory event.

Where the setup sits:

  • The recent business combination with Horizon Space Acquisition II Corp completed the SPAC-listing path onto Nasdaq — converted the entity from private-development-stage to publicly-listed with associated disclosure.
  • The Orphan Drug Designation request to the FDA for GDT cell therapy targeting glioblastoma is the substantive regulatory event: designation carries meaningful clinical-development and commercial-launch incentives.
  • The exhibition of brain-cancer therapy research at the 2026 World Congress of Basic and Clinical Pharmacology adds scientific-community validation, but exhibition-level presentation is preliminary versus clinical-trial results.
  • Ching-Dong Wang Form 3 disclosing 334M ordinary shares (329M through SL Link Holdings) confirms controlling ownership — tightly held with a small public float.

The next pivot is FDA orphan-drug designation decision plus any Phase 1 clinical-trial timeline visibility: substantive Orphan Drug Designation grant plus firm clinical-development cadence is what breaks the current opacity; a rejection or unrelated regulatory-headline setback and the -66% 12M drawdown extends as the post-SPAC scrutiny deepens.

Agrees with X sentimentX captures the substance — SLBT referenced as a low-float runner archetype with traders citing it as a comparison point for other small-float Israeli and microcap names like WXM, INHD, EHGO, and NXTS. The mentions are retrospective, framing SLBT's prior squeeze move as the template others are trying to repeat — the positive momentum-oriented tone around the SLBT precedent reflects tape mechanics rather than fundamental conviction.

What to watch: FDA orphan drug designation decision plus any Phase 1 clinical trial timeline visibility — substantive designation grant plus firm clinical-development cadence breaks the opacity; rejection or unrelated regulatory setback and the -66% 12M drawdown extends.

On the calendar: FDA Orphan Drug Designation decision

technicals missing

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-06-24

SLBT is referenced as a low-float runner archetype, with traders citing it as a comparison point for other small-float Israeli and microcap names like WXM, INHD, EHGO, and NXTS. The mentions are retrospective, framing SLBT's prior squeeze move as the template others are trying to repeat. Tone around the SLBT precedent is positive momentum-oriented.

Read the AI verdict + X sentiment for $SLBT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Blank check company (SPAC) formed to identify and complete a strategic business combination with one or more target companies.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SLBT.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $SLBT

Neutral — Blank check company (SPAC) formed to identify and complete a strategic business combination with one or more target companies; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
0.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-20.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-35.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
20.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-25.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
57.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.—Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 6.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13DActivist position (5%+)Jun 18SC 13D
AI summary

Ching-Dong Wang (Taipei, Taiwan) filed an initial Schedule 13D for SL Science Holding Ltd (SLBT) as of June 12, 2026, representing new controlling-owner and director disclosure. Wang appears to be the company's controlling founder given the dominant ~333M share stake disclosed in the accompanying Form 3. New controlling-holder 13D for SLBT — Wang's 5%+ disclosure initiates the required Schedule 13D reporting as the company's founding and controlling shareholder.

3New insider — initial holdingsJun 183
AI summary

Ching-Dong Wang filed an initial Form 3 for SL Science Holding Ltd (SLBT), reporting 333,832,129 ordinary shares including 329,286,823 held by SL Link Holdings and additional direct shares. This represents controlling ownership — Ching-Dong Wang effectively controls SLBT through SL Link Holdings, with a dominant ~333.8M share position that gives him decisive influence over the company.

3New insider — initial holdingsJun 173
AI summary

Qian Xu filed an initial Form 3 for SL Science Holding Ltd, reporting 20,000 directly-owned ordinary shares as of June 17, 2026. Routine initial insider disclosure — small equity position.

3New insider — initial holdingsJun 163
AI summary

Johnson Lau filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

3New insider — initial holdingsJun 163
AI summary

Ethan Shen filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

3New insider — initial holdingsJun 163
AI summary

Mingche Liu filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

3New insider — initial holdingsJun 163
AI summary

Kwo-Liang Chen filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

3New insider — initial holdingsJun 163
AI summary

John C. General filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

+ 11 other (3 425s · 2 6-Ks · 2 3s · 1 F-1) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacologyglobenewswire.com·17d agoSL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastomaglobenewswire.com·24d agoSL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com·42d agoSL Science Holding Limited Reports Full Year 2025 Financial Resultsglobenewswire.com·46d agoSL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Marketglobenewswire.com·52d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$CAPR$IBRX$REGN$AURA$HALO$ALLO$MRNA
Voices on X · last 7 days

No standout posts about $SLBT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport